{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-016445","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2024-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.334106+00:00","generated_at":"2026-05-28T23:29:16.677941+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Protalix repays all convertible notes, becomes debt-free; EMA validates Fabry drug dosing variation","bullets":["Repaid in full all outstanding convertible notes, making company debt-free.","EMA validated Chiesi's variation submission for pegunigalsidase alfa every-four-week dosing in EU.","Completed Phase I trial of PRX-115 for uncontrolled gout; Phase II planned H2 2025.","Revenue streams from Elfabrio, Elelyso, and Uplyso growing; full operations maintained despite Israel conflict.","Fine-tuned R&D strategy on renal rare diseases and plant-based drug delivery."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-016445","json":"https://secwatch.observer/filing/0001558370-24-016445.json","markdown":"https://secwatch.observer/filing/0001558370-24-016445.md","text":"https://secwatch.observer/filing/0001558370-24-016445.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837024016445/0001558370-24-016445-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837024016445/plx-20241223x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T23:29:16.677941+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}